chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Tiredness, queasy stomach, low energy, lethargic, headache, swelling and pain at injection site
there was a bruise on injection site; On 9th Day, she noticed some rash on side of injection site; On 8th day, patient felt itching at injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE BRUISING (there was a bruise on injection site), INJECTION SITE PRURITUS (On 8th day, patient felt itching at injection site) and INJECTION SITE RASH (On 9th Day, she noticed some rash on side of injection site) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023MWA) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included FEXOFENADINE HYDROCHLORIDE (ALLEGRA), LANSOPRAZOLE (PREVACID), MELOXICAM and ERGOCALCIFEROL, RETINOL PALMITATE (VITAMINS A & D) for an unknown indication.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, the patient experienced INJECTION SITE PRURITUS (On 8th day, patient felt itching at injection site). On 11-Mar-2021, the patient experienced INJECTION SITE BRUISING (there was a bruise on injection site) and INJECTION SITE RASH (On 9th Day, she noticed some rash on side of injection site). On 12-Mar-2021, INJECTION SITE BRUISING (there was a bruise on injection site) had resolved. At the time of the report, INJECTION SITE PRURITUS (On 8th day, patient felt itching at injection site) and INJECTION SITE RASH (On 9th Day, she noticed some rash on side of injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medication was not provided by the reporter.
This is a cluster of 2 unidentified patients' who experienced similar adverse events following vaccination with FLUZONE. Initial report received from a health care professional on 21 October 2010. A group of 2 unidentified patients' received an injection (route and site not reported) of FLUZONE, lot number U3703AA. The two patients have got cellulitis at the injection site. No additional information was provided. The outcome was not reported. Follow-up information was received from a health care professional on 07 December 2010. The patients' had no illness at the time of vaccination. No further information was reported at the time of the report. The patient's outcomes were reported as recovered (date not reported). Documents held by sender: None.
AFTER WAITING 15MIN, PATIENT WAS ABOUT TO LEAVE THEM EXPIERENCED NAUSEA/DIZZINESS ALONG WITH SEEING DARK SPOTS. PT WAS ALSO TACHYCARDIC WITH HIGH BLOOD PRESSURE. 911 WAS CALLED  AS PT BEGAN TO SHAKE. PARAMEDICS CAME AND PT WENT TO HOSPITAL. PT DID NOT LOSE CONSCIOUSNESS OR HAVE DIFFICULTY BBREATHING.
On 02/22/2022 I had my 4th vaccination with Moderna. About 6-8 weeks after, I noticed it was itchy at the vaccination site. I thought possible mosquito bit. It got worse and worse as time went on going from half dollar to now the size of my palm. It is rough feeling to the touch. Treatment included triamcinolone acetamide but it didn't work. I use CALADRYL that seems to work. It is still present on my arm.
Injection site reaction: Swelling, warmth, redness, itchiness, goose-bump-like rash, mild pain around injection site. Became noticeable 18 hours after injection, and it is still noticeable 24 hours after onset.
body aches // 2nd dose; severe headaches // 2nd dose; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 26-Feb-2021 and was forwarded to Moderna on 27-Feb-2021.    This spontaneous case was reported by a consumer and describes the occurrence of PAIN (body aches // 2nd dose) and HEADACHE (severe headaches // 2nd dose) in a 38-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016M20A and 013L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-Feb-2021, the patient experienced PAIN (body aches // 2nd dose) and HEADACHE (severe headaches // 2nd dose). At the time of the report, PAIN (body aches // 2nd dose) and HEADACHE (severe headaches // 2nd dose) outcome was unknown.            This case was linked to MOD-2021-055488 (Patient Link).
pharmacist punctured a vial and the vial was put back in the refrigerator and the next day, 24 hrs later, 5 doses were administered to 5 patients.; pharmacist punctured a vial and the vial was put back in the refrigerator and the next day, 24 hrs later, 5 doses were administered to 5 patients.; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (pharmacist punctured a vial and the vial was put back in the refrigerator and the next day, 24 hrs later, 5 doses were administered to 5 patients.) and WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (pharmacist punctured a vial and the vial was put back in the refrigerator and the next day, 24 hrs later, 5 doses were administered to 5 patients.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Apr-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (pharmacist punctured a vial and the vial was put back in the refrigerator and the next day, 24 hrs later, 5 doses were administered to 5 patients.) and WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (pharmacist punctured a vial and the vial was put back in the refrigerator and the next day, 24 hrs later, 5 doses were administered to 5 patients.). On 22-Apr-2021, EXPIRED PRODUCT ADMINISTERED (pharmacist punctured a vial and the vial was put back in the refrigerator and the next day, 24 hrs later, 5 doses were administered to 5 patients.) and WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (pharmacist punctured a vial and the vial was put back in the refrigerator and the next day, 24 hrs later, 5 doses were administered to 5 patients.) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Most recent FOLLOW-UP information incorporated above includes: On 28-May-2021: Follow up  received on 28-May-2021 and does not contain any new information
Systemic: Chest Tightness / Heaviness / Pain-Mild, Systemic: Dizziness / Lightheadness-Medium, Systemic: Flushed / Sweating-Severe, Systemic: Nausea-Medium, Additional Details: Patient had profuse sweating after COVID vaccine, accompanied by nausea and dizziness. After patient reported chest tightness, 911 was called. An ambulance arrived to monitor patient (blood pressure, vital signs, etc). Paramedics took over care, however patient began to improve quickly and was feeling better by the time they arrived.
first dose three years ago/Inappropriate Schedule of vaccine; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received, 3 years ago of reporting date).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. Till the time e of reporting, the patient did not receive the second dose of the Shingrix vaccine, which led to incomplete course of vaccination. The reporter consented to follow up.
One day post vax the pt experienced a rash from the shoulder to the elbow of the arm where he received the injection. The pt's rash persisted at the time of the report. The reporter was "not sure if it was a hypersensitivity reaction".
On 4/1/02, developed fever of 102F, fine red rash on face, neck and trunk of body and swollen lymph nodes under jaw and back of neck. Her fever was off and on for 3 days. The rash was present X 8 days and was itchy. She was seen by a physician on 4/26/02 and was given Benadryl and Tylenol.
hand blisters that I was treated for at my primary care physician. extreme chest discomfort of heaviness, difficulty breathing, and very rapid heart rate for 7 days.
On June 8, 2021 I noticed right shoulder/arm pain. Went to my dr on 6/9 and he ordered a port dye study (I have a Bard Power Port for iron infusions that ended in February). The port was fine, everything flowing correctly.  On 6/10, my right arm was swollen and discolored. My Dr told me to go to ER.  A CT scan was  done and  showed 2 DVTs and 1 PE. I was admitted and started on IV heparin. I was on the IV heparin until 6/13 and then was switched to oral Eloquis 10mg twice daily. It is now 6/14, and I should be discharged sometime today. I will continue to be on Eloquis for 3 - 6 months.
24 hours after vaccine was administered. Mother removed band aid from injection site Right deltoid arm became red, hot to touch, swollen and itchy for three days. Mother noted child had no fever.
hoarseness, chills, cough, malaise, fever starting 2 days p/vax;
Information has been received from a licensed practical nurse concerning a 12 month old male with no pertinent medical history who on 7/13/2006 was vaccinated with a dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (+) varicella virus vaccine live (upgrade process) (lot 652329/1130R). Subsequently, on 7/13/2006 the patient developed croup and wheezing. Unspecified medical attention was sought and he was treated with a moderate dose of steroids. No laboratory diagnostic test were performed. At the time of the report the patient had not recovered. There was no product quality complaint involved. The patients croup was considered to be an other important medical event (OMIC). Additional information has been requested.
Admission Date: 8/11/2022 Discharge Date: 8/13/2022  DISCHARGE DIAGNOSES 1. Acute delirium, multifactorial 2. COVID-19 3. Asymptomatic pyuria 4. Chronic combined systolic and diastolic heart failure 5. Angiosarcoma of the scalp, suspicion for metastasis  HOSPITAL COURSE: Patient is a 84 y.o. female with a past medical history significant for angiosarcoma of the scalp, HTN, essential tremor, ulcerative colitis s/p ileal resection with colostomy, aortic stenosis s/p TAVR, combined CHF, and hypothyroidism. She presented to the ED on 8/11/2022 after she reportedly fell at home and had been increasingly confused per family's report. She had no loss of consciousness nor did she suffer a head injury.   On arrival to the ED, patient was afebrile however COVID positive. Physical exam noted generalized weakness. Urinalysis was positive for WBC but symptomatic UTI was ruled out. Initial CBC, CMP, TSH, and glucose were unremarkable. CXR unremarkable for acute intrathoracic process. EKG unremarkable for acute myocardial ischemia. There was insignificant difference in initial and 2-hour troponin.  CT head unremarkable for acute bleed however it showed a 10 mm soft subcutaneous density in the right parotid. CT spine ruled out fractures. Patient was admitted to the general medical floor for further evaluation of weakness and cause of fall.   On the medical floor, EEG, blood cultures, and urine drug screen were obtained. Active seizures, infection, and substance abuse were ruled out as a cause of the patient's fall. With concern for acute CVA and negative initial head CT, MRI of the head was obtained. There was no evidence of infarction, hemorrhage, or intracranial metastasis, however mild chronic microvascular ischemic disease and mild cerebral atrophy were noted.    Patient's mental status returned back to baseline over course of admission. The medical team discussed with patient that many ominous causes of her fall were ruled out. Patient had classic signs and symptoms of acute delirium. This diagnosis was discussed with the patient and her family in detail. It was recommended by the primary medical team that the patient follow up with PCP and be referred to a neurologist for formal memory testing.    On 8/13/22, patient was medically and vitally stable for discharge home with family.
Swelling in the entire upper arm, no fever. Advised warm soaks and pt recovered in two days. Swelling beyond normal local reaction.
PATIENT RECEIVED THE SHINGRIX VACCINE ON EXPERIENCED RASH ON INJECTION SITE THE NEXT DAY AND ON BOTH SIDES OF NECK ON 11/30.
Swollen tongue, headache, chills, difficulty swallowing, dry mouth - within 15-25 mins of injection.  Condition peaked around 30mins and stabilized/improved.  Itchy rash on forehead appeared about 90mins post-injection.
Left side of neck swollen lymph nodes; fatigue; This is a spontaneous report from a contactable other hcp.    A 53-years-old female patient received bnt162b2 (BNT162B2 PFIZER-BIONTECH COVID-19 MRNA VACCINE; Solution for injection (Batch/Lot Number: EL9261; Expiration Date: 31May2021), dose 2 intramuscular, administered in Arm Right on an unspecified date (Batch/Lot Number: EL9261; Expiration Date: 31May2021) as dose 2, single for covid-19 immunisation. Medical history included, sinusitis placed on Ceftin 500 mg BID (Twice a day)x21 days, otitis media, placed on Ceftin 500 mg BID (twice a day)x 21 days, thyroid mass patient was seeing endocrinologist but HCP is not sure patient has seen them since 2015 , hypothyroidism patient takes Synthroid , hypertension, sepsis. Patient has a niece with a haematological symptom, anxiety. Concomitant medication(s) included cefuroxime axetil (CEFTIN [CEFUROXIME AXETIL]) taken for sinusitis, otitis media; escitalopram oxalate (LEXAPRO) taken for anxiety, depression; estradiol (ESTRADIOL); hydroxyzine embonate (VISTARIL [HYDROXYZINE EMBONATE]; levothyroxine sodium (SYNTHROID) taken for hypothyroidism,; lisinopril (LISINOPRIL) taken for hypertension; vitamin d3 (VITAMIN D3) taken for vitamin d decreased; prednisone (PREDNISONE) taken for arthralgia, swelling, headache from 05Jan2021 to an unspecified stop date. The patient did not receive any other vaccine in four weeks. Prior to vaccination patient was not diagnosed with COVID. Post vaccination patient did not test for COVID.It was reported that, the patient experienced left side of neck swollen lymph nodes and fatigue on an unspecified date with outcome of recovered. The patient underwent lab tests and procedures which included antinuclear antibody: normal on 05Jan2021, blood uric acid: normal on 05Jan2021, computerised tomogram: normal on 08Jan2021, c-reactive protein: 5.0 on 05Jan2021 High, full blood count: normal on 05Jan2021, metabolic function test: normal on 05Jan2021, red blood cell sedimentation rate: 30 on 05Jan2021 High, rheumatoid factor: normal on 05Jan2021, vitamin d: 20 on 05Jan2021 Low. Therapeutic measures were taken as a result of left side of neck swollen lymph nodes (lymphadenopathy), fatigue (fatigue
Dizziness, doesn't move head in order to alleviate it; Nausea, doesn't move head in order to alleviate it; Vomiting; Weakness; This case was reported by a consumer via call center representative and described the occurrence of dizziness in a 79-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 4th April 2022, the patient received the 1st dose of Shingrix. On 4th April 2022, 7 hrs after receiving Shingrix, the patient experienced dizziness, nausea, vomiting and weakness. On an unknown date, the outcome of the dizziness, nausea, vomiting and weakness were not recovered/not resolved.   It was unknown if the reporter considered the dizziness, nausea, vomiting and weakness to be related to Shingrix.     Additional Information: GSK Receipt Date: 8-APR-2022 Reporter's comment: The reporter was the daughter of the patient. The reporter reported that the patient received her first dose of Shingrix at 3 pm, at 10 pm (Post meridiem) the same day, the patient began experiencing dizziness, nausea, vomiting, and weakness.  The patient's symptoms have not worsened or subsided at the reporting time.  The patient does not move her head in order to alleviate the nausea and dizziness.  Spoke per content. Gave Medical Advice Disclaimer. Referred to HCP (health care professional) The reporter did not wish to provide any further information or details. The reporter did not consented to follow-up.
soreness at injection site; fatigue; joint pain; This is a spontaneous report from a contactable consumer (patient). A 61-year-old female patient (not pregnant at time of vaccination) received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 09Apr2021 at 14:15 (lot number: ew0162) on the left arm as single dose for COVID-19 immunization. Medical history was not reported. Concomitant medications included ibuprofen (ADVIL [IBUPROFEN]) and loratadine that received within 2 weeks of vaccination. The patient previously took the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 19Mar2021 at 14:15 (lot number: er2613) on the left arm as single dose for COVID-19 immunization; and on 19Mar2021, patient experienced injection site pain and soreness, fatigue, extreme thirst. Patient previously also took codeine family and experienced allergies. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient did not diagnose with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 10Apr2021, patient experienced soreness at injection site, fatigue, joint pain. There was no treatment received for the adverse event. The outcome of the events was recovered on unspecified date.   No follow-up attempts are needed. No further information is expected.
Pt given entire vial of COVID19 vaccine on 5/1.  No reported signs/ symptoms at this time.
Hospitalized for increased dyspnea, had a cold for about 3 weeks prior.
Patient received Hepatitis-B Vaccine on 03/17/2003 Since that night infant has been having excessive crying and Colic symptoms. Infant has been feeding, voiding and stooling well.No fever. No local reactions at the vaccine injection site have been noticed. Medical exam normal for age.
This spontaneous report was received from a registered nurse and refers to multiple patients of an unknown gender and age. The patients' concurrent conditions, medical history and concomitant therapy were not reported. On unknown dates, the patients were vaccinated with an unspecified number of doses of improperly stored VAQTA lot # L002717, expiration date: 02-JUN-2017 (dose and route of administration were not reported). There were no adverse effects reported. This is one of several reports received from the same source. Additional information has been requested.
I got cellulitis because the lady didn't properly clean it. Then i called told them what was going on and they told me just to keep an eye on it btw it was warm to the touch and swollen bad and rock hard. I even went back up there and had them look at it twice and they just kept saying it was a normal reaction to the injection. I finally went to ER becuase i felt super sick and not like i caught a cold i felt sick inside.
On 10/07/2000 the patient was seen in the physician's office "with lesions on abdomen/belly and back that were increasing in number (spreading)." The approximate number was unknown. It was reported that the patient's condition subsequently resolved. Follow up information indicated that the patient was not seen in the physician's office. The patient's experiences were reported by the patient's mom per phone. No further information is available.
Subsequent to plaintiff's ZOSTAVAX inoculation, Plaintiff was treated by a healthcare provider, for shingles.; Information has been received from a lawyer regarding a case in litigation concerning a male patient (pt) of unknown age. No information was received regarding the pt's past medical history, concurrent conditions, or concomitant medication. On or about 30-SEP-2014, the pt was inoculated with the zoster vaccine live (ZOSTAVAX) (lot number, dosage and route of administration not provided), as prescribed and/or administered by a physician, for the long-term prevention of shingles and zoster-related conditions. Alternatively, on or about 30-SEP-2014, the pt's healthcare providers, relied on the warning label affixed to the zoster vaccine live (ZOSTAVAX) vaccine, believed that it was effective in preventing shingles on a long-term or permanent basis, and believed that it did not carry any significant risks of adverse effects. Subsequent to pt's zoster vaccine live (ZOSTAVAX) inoculation (unknown date), pt was treated by a health care provider, at Medical Center, for shingles. As a direct and proximate result of pt's use of the zoster vaccine live (ZOSTAVAX) vaccine, pt had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future.
In late January 2023 I thought I had a sinus infection. My face hurt and I had a headache. Everything hurt in my head.  I went to the doctor and tested positive for COVID-19. I had fatigue, muscle aches, diarrhea, vomiting. I took Paxlovid.  I began to feel better after another week. It took another two weeks to feel like I was over COVID-19. It then took another two weeks before I had my energy. I also have fluid in my ears that has been there since my infection.
sore swollen arm; sore swollen arm; nausea; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID.  A female patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious), PERIPHERAL SWELLING (non-serious), outcome "unknown" and all described as "sore swollen arm"; NAUSEA (non-serious), outcome "unknown".  Additional information: The patient received the Pfizer vaccine herself and experienced some of those symptoms such as a sore swollen arm, nausea etc.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
ENTIRE LEFT ARM SWELLING , SOUGHT URGENT CARE, PRESCRIBED BENADRYL AND ANTIBIOTICS.